Abstract:Halogen bond has attracted a great deal of attention in the past years for hit-to-lead-to-candidate optimization aiming at improving drug-target binding affinity. In general, heavy organohalogens (i.e., organochlorines, organobromines, and organoiodines) are capable of forming halogen bonds while organofluorines are not. In order to explore the possible roles that halogen bonds could play beyond improving binding affinity, we performed a detailed database survey and quantum chemistry calculation with close attention paid to (1) the change of the ratio of heavy organohalogens to organofluorines along the drug discovery and development process and (2) the halogen bonds between organohalogens and nonbiopolymers or nontarget biopolymers. Our database survey revealed that (1) an obviously increasing trend of the ratio of heavy organohalogens to organofluorines was observed along the drug discovery and development process, illustrating that more organofluorines are worn and eliminated than heavy organohalogens during the process, suggesting that heavy halogens with the capability of forming halogen bonds should have priority for lead optimization; and (2) more than 16% of the halogen bonds in PDB are formed between organohalogens and water, and nearly 20% of the halogen bonds are formed with the proteins that are involved in the ADME/T process. Our QM/MM calculations validated the contribution of the halogen bond to the binding between organohalogens and plasma transport proteins. Thus, halogen bonds could play roles not only in improving drug-target binding affinity but also in tuning ADME/T property. Therefore, we suggest that albeit halogenation is a valuable approach for improving ligand bioactivity, more attention should be paid in the future to the application of the halogen bond for ligand ADME/T property optimization.

The Important Role of Halogen Bond in Substrate Selectivity of Enzymatic Catalysis

Insight into the Role of Halogen Bond in the Activity of D-Mandelate Dehydrogenase Toward Halogenated Substrates

Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors.

Halogen Bond Catalysis: A Physical Chemistry Perspective

Highly Enantioselective Organocatalysis with Bidentate Halogen Bond Donors

Turning noncovalent interactions via halogen substituents for improving activity and enantioselectivity of Candida antarctica lipase B

Halogen Bond: Its Role Beyond Drug-Target Binding Affinity for Drug Discovery and Development.

Halogen bonding for rational drug design and new drug discovery.

Structure-guided Stereoselectivity Inversion of a Short-Chain Dehydrogenase/reductase Towards Halogenated Acetophenones.

Nonbonding interactions of organic halogens in biological systems: implications for drug discovery and biomolecular design.

Structural Insight into the Catalytic Mechanism of Non-Heme Iron Halogenase AdaV in 2′-Chloropentostatin Biosynthesis

Cross-assembly confined bifunctional catalysis via non-covalent interactions for asymmetric halogenation

Perfect Partners: Biocatalytic Halogenation and Metal Catalysis for Protein Bioconjugation

Application of Cation-Π Interactions in Enzyme-Substrate Binding: Design, Synthesis, Biological Evaluation, and Molecular Dynamics Insights of Novel Hydrophilic Substrates for NQO1.

Pnictogen, chalcogen, and halogen bonds in catalytic systems: theoretical study and detailed comparison

Proton Transfer Can Govern Regioselectivity Assisted by Iron Catalysis.

The applications of catalytic asymmetric halocyclization in natural product synthesis

Rediscovery of halogen bonds in protein-ligand complexes.

Advances of Haloperoxidases-Catalyzed Green Halogenation Reactions

Selective hydrogenation via precise hydrogen bond interactions on catalytic scaffolds

Programmable late-stage C−H bond functionalization enabled by integration of enzymes with chemocatalysis